Affitech A/S strengthens its IP portfolio on anti-VEGF antibody AT001/r84
Affitech A/S announced that the U.S. Patent and Trademark Office (USPTO) has granted Affitech U.S. patent (no. 8,034,905) covering the Company’s anti-VEGF antibody drug candidate AT001/r84. The newly granted US patent is the first patent grant Affitech has received for this compound in a major territory and it considerably strengthens Affitech's IP position regarding this drug candidate. The patent is co-owned by Affitech and its collaboration partner Peregrine Pharmaceuticals.
Commenting on the new patent, Managing Director of Affitech A/S Martin Welschof said: “The grant of the patent on AT001/r84 by the USPTO is pleasant news. We hereby extend our patent portfolio for AT001/r84 to include USA, which is important for the further development of this antibody drug candidate. The development of AT001/r84 is progressing well and IBC Generium expects to commence the first phase 1 clinical trial with the drug candidate before year end 2011.”
AT001/r84 is a proprietary therapeutic antibody to vascular endothelial growth factor (VEGF) being developed by Affitech and IBC Generium as a potential alternative to bevacizumab (Avastin®) for the treatment of certain human cancers. The Russian health authorities have identified cancer therapy based on anti-VEGF antibodies as one of the top priority areas of pharma-innovation in Russia. Affitech’s AT001/r84 has the potential to satisfy patient needs in this area. The rights to develop and commercialize AT001/r84 outside Russia and the CIS remain with Affitech.
Affitech A/S announced that the Company has received 2.5 million Euro in milestone payment from IBC Generium. The payment is related to the delivery of the preclinical package for Affitech’s anti VEGF antibody AT001/r84 to its Russian collaboration partner IBC Generium, who will use the pac ... more
Affitech A/S announced that Dr Martin Welschof, its Managing Director, will leave his position at the end of the year. The Board of Directors has accepted his resignation with effect from 31st December, 2011 and will consider potential candidates to succeed him during the coming weeks.Dr Al ... more
Affitech A/S announced that IBC Generium has exercised the license to Affitech’s lead anti-VEGF antibody drug candidate AT001/r84. The license grant triggered a payment of Euro 2.5 million by IBC Generium to Affitech A/S and provides IBC Generium with the exclusive rights to develop and mar ... more
Affitech is a privately held biotechnology company based in Oslo, Norway, that has developed a comprehensive package of innovative technologies for the generation and use of human antibodies. The most significant aspect of the Company’s proprietary technologies includes its dominant worldwi ... more
Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 8,759,102 and US Patent No. 8,779,236 with fundamental claims directed to RNAi in cells and organisms to effect gene silencing. These two new patents granted add to t ... more
Plant Bioscience Limited (PBL) announced that the United States Patent and Trademark Office (USPTO) has issued out US Patent No. 8,258,285 with fundamental claims directed to compositions to effect gene silencing and US Patent No. 8,263,569 with fundamental claims directed to methods of ind ... more
Verona Pharma plc announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554. The patent is the fourth patent issued for RPL554 and related compounds in the US.RPL554, Verona Pharma's lead drug candidate, is a dual pho ... more